FibroGen, Inc (NASDAQ:FGEN) Director Jorma Routti sold 12,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $47.25, for a total value of $567,000.00. Following the transaction, the director now directly owns 133,840 shares of the company’s stock, valued at $6,323,940. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

FibroGen, Inc (NASDAQ FGEN) traded down $2.65 on Monday, hitting $44.50. The stock had a trading volume of 451,259 shares, compared to its average volume of 618,471. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen, Inc has a 1-year low of $19.25 and a 1-year high of $60.15.

FGEN has been the subject of a number of research reports. Jefferies Group reaffirmed a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, September 12th. Mizuho reaffirmed a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. Stifel Nicolaus reissued a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research note on Thursday, September 14th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Citigroup raised their price objective on FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $65.67.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in shares of FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 412 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of FibroGen by 1.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 474 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 696 shares during the period. Tudor Investment Corp ET AL boosted its position in shares of FibroGen by 7.1% in the second quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after buying an additional 799 shares during the period. Finally, Amalgamated Bank boosted its position in shares of FibroGen by 15.0% in the third quarter. Amalgamated Bank now owns 8,423 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 1,097 shares during the period. 57.42% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Jorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/04/jorma-routti-sells-12000-shares-of-fibrogen-inc-fgen-stock.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.